Corbevax will be the second vaccine after Covaxin which has received EUA for those below 18 years of age. The Hyderabad-based pharmaceutical company will be submitting data soon for clinical trials done on children aged below 12 years, the news agency added.
The DCGI has already approved Corbevax, which is India's first indigenously developed RBD protein sub-unit vaccine against Covid-19, for restricted use in emergency situations among adults on December 28.
The Corbevax vaccine is administered through an intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees Celsius temperatures and presented as 0.5 ml (single dose) and 5 ml (10 doses) vial pack.
The expected cost of the vaccine is ₹145 excluding taxes. ANI citing government sources said that the central government has placed an order for Corbevax.